Insmed's (INSM) brensocatib offering, "likely to be among the strongest launches in 2025," will be driven by high patient and physician demand for the chronic lung disease treatment, RBC Capital Markets said Monday in a report.
The drug, which will likely be approved with a clean label by Aug. 12, may reach a peak sales opportunity of $8.2 billion for bronchiectasis treatment with $53 million in 2025 sales, the investment firm said.
The drug has potential beyond bronchiectasis with mid-2025 data on chronic rhinosinusitis without nasal polyps possibly offering a $1 billion market opportunity, while 2026 data from trials of hidradenitis suppurativa, a chronic skin conditions, may expand brensocatib into specialty dermatology, adding $300 million in sales, RBC said.
Mycobacterium avium complex lung disease treatment Arikayce is expected to generate $425 million in 2025 sales and may expand if a phase 3 trial is successful, driving revenue to $1 billion, RBC said.
RBC initiated coverage on Insmed with an outperform rating and a $100 price target.
Shares of the company fell 3% in recent Tuesday trading.
Price: 77.63, Change: -2.40, Percent Change: -3.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。